Clinical trials: Temozolomide
Malignant Gliomas
Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
Temozolomide is the standard adjuvant chemotherapy of newly-diagnosis malignant gliomas.Cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of TMZ.
- Trial name
- NCT01670890
- Testing
- TMZ, TMZ plus CDDP
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Glioblastomas, Gliosarcoma
Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma
Standard treatment for glioblastomas includes radiation and chemotherapy with a drug called temozolomide (Temodar); however, glioblastomas frequently develop resistance to standard treatment and recur or progress.
- Trial name
- HBO (NCT00936052)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Neurological Surgery, P.C.
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT…
- Trial name
- NCT04396860
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab
- Where
- 285 sites in United States
- Volunteers
- 159 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the…
- Conditions
- Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02595424
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 673 sites in United States
- Volunteers
- 67 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Glioma
Hypofractionated IMRT With Temozolomide for HGG
To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed HGGs after surgery.
- Trial name
- NCT02082119
- Testing
- Hypofractionated IMRT
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Extrapancreatic Neuroendocrine Tumor
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced…
- Trial name
- NCT03204032
- Testing
- Tegafur, Temozolomide, Thalidomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese Academy of Medical Sciences
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Neuroendocrine Tumor With Liver Metastases
Lenvatinib Plus Chemotherapy for pNET Liver Metastases
This prospective, non-randomized, concurrent parallel-controlled study will evaluate treatment response and resistance mechanisms in patients with pancreatic neuroendocrine tumors with liver metastases (pNET-LM) receiving…
- Trial name
- LEN-pNET (NCT07835893)
- Testing
- Lenvatinib, Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Glioblastoma Multiforme
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
This study will combine the chemotherapy agent temozolomide with the investigational drug SCH66336 (an agent which interferes with new cell growth).
- Trial name
- NCT00038493
- Testing
- Temozolomide and SCH66336
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Glioblastoma
Carbon Ion Radiotherapy for Primary Glioblastoma
Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons.
- Trial name
- CLEOPATRA (NCT01165671)
- Testing
- Carbon Ion Radiotherapy, Proton Radiotherapy
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University Hospital Heidelberg
Glioblastoma
Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
This is a multi-center, phase II/III, open-label, randomized, parallel and standard chemoradiation-controlled study where eligible subjects will be randomized at 1:1 ratio to receive control treatment or study treatment.
- Trial name
- NCT03008148
- Testing
- CCRT, Temozolomide, Siroquine
- Where
- 2 sites in Taiwan
- Volunteers
- 288 people
- Sponsor
- Johnpro Biotech, Inc.
Glioblastoma
Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery
The purpose of this study is to explore the effects of Vebreltinib in primary glioblastoma patients receiving a combination therapy of chemotherapy (temozolomidel) and MET-TKI.
- Trial name
- NCT06780592
- Testing
- Vebreltinib + Temozolomide, Temozolomide
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Recurrent Glioblastoma, IDH-Wildtype
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma.
- Trial name
- Cerebraca-02/3 (NCT07349693)
- Testing
- Cerebraca wafer, Temozolomide (for relapsed malignant glioma)
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Everfront Biotech Co., Ltd.
Glioblastoma
Iodine-125 Brachytherapy Together With Chemotherapy in Patients With Newly Diagnosed Glioblastoma
The purpose of this study is to evaluate the efficacy and safety of Iodine-125 brachytherapy together with chemotherapy compared with surgical resection followed by concomitant radiochemotherapy in patients with newly diagnosed…
- Trial name
- IBCNG (NCT04856852)
- Testing
- Iodine-125+Chemotherapy, Surgical resection+Radiochemotherapy
- Volunteers
- 84 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Lymphoma
Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine
The purpose of this study is to evaluate two types of chemotherapy for primary central nervous system lymphoma in the elderly (age older than 60) : Methotrexate, procarbazine, vincristine and cytarabine Methotrexate and…
- Trial name
- CNSLymphoma (NCT00503594)
- Testing
- Methotrexate and temozolomide, Methotrexate , procarbazine ,vincristine ,cytarabine
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain and Central Nervous System Tumors
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
RATIONALE: Lonafarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00083096
- Testing
- lonafarnib, temozolomide
- Where
- 3 sites in France, Switzerland
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Neuroblastoma
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or Topotecan-Temozolomide) demonstrates activity…
- Trial name
- BEACON (NCT02308527)
- Testing
- Bevacizumab, Temozolomide, Irinotecan
- Where
- 10 sites in Austria, Belgium and 8 more
- Volunteers
- 225 people
- Sponsor
- University of Birmingham
Glioblastoma
Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma
Glioblastoma is an aggressive type of brain cancer. Standard treatment usually includes three weeks of radiation therapy alone or combined with chemotherapy using Temozolomide.
- Trial name
- TEMPO (NCT07476794)
- Testing
- Daily TMZ
- Where
- Canada
- Volunteers
- 118 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic, Cerebral Primitive Neuroectodermal Tumors
Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years
Primary objective : To increase the 3 year progression-free survival from 40% to 60%. Patients included : metastatic, cerebral primitive neuroectodermal tumors in children aged over 5 years.
- Trial name
- NCT00936156
- Testing
- Chemotherapy (carboplatin, etoposide, thiotepa)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Glioblastoma
Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma
This is an open-label, single arm, Phase 1 study to assess the safety and tolerability of macitentan in combination with dose-dense temozolomide in adult patients with recurrent glioblastoma or gliosarcoma.
- Trial name
- NCT01499251
- Testing
- Phase 1 Dose Escalation, Phase 1b, Ancillary Study
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Actelion